Jennings becomes President of Beckman Coulter Diagnostics

pharmafile | October 19, 2026 | Appointment | |  Beckman Coulter Diagnostics, Corporate, Diagnostics, appointments 

Beckman Coulter Diagnostics has appointed Catherine Jennings as its new President. 

In this role, Jennings will lead the company’s strategic, operational and organisational priorities, applying a culture of continuous improvement to accelerate innovation, strengthen global impact and help laboratories and clinicians deliver better patient outcomes.

She brings more than 20 years of healthcare industry leadership experience and joins the company from Boston Scientific, where she was most recently President of Vascular Therapies, leading a global business of approximately US$2bn in annual revenue.

Advertisement

“Cat is an accomplished healthcare leader with a strong track record of driving growth, fostering innovation and developing high-performing teams,” said Kevin O’Reilly, Group Executive of parent company Danaher Diagnostics. 

“As part of Danaher’s connected diagnostics ecosystem, Beckman Coulter Diagnostics brings together deep expertise, global scale and customer partnership to address some of healthcare’s toughest challenges. Cat’s leadership will help us accelerate innovation and expand the impact of diagnostic solutions around the world.”

Related Content

Functional lung imaging offers new possibilities for respiratory care

Advances in computed tomography (CT) technology are helping to reshape the diagnosis and management of …

NanoSomiX and Beckman Coulter Diagnostics collaborate on blood tests for neurodegenerative diseases

NanoSomiX and Beckman Coulter Diagnostics have announced plans to collaborate on the development of next-generation …

InnotiveDx gets £1m grant to advance UTI diagnostics system

InnotiveDx has announced that it has received a £1m grant from Pathways to Antimicrobial Clinical …

The Gateway to Local Adoption Series

Latest content